$10.15
0[0.00%]
At close: Apr 24
$10.15
0[0.00%]
PreMarket: 4:00PM EDT
Olema Pharmaceuticals
(NASDAQ:OLMA)Olema Pharmaceuticals Stock (NASDAQ:OLMA), Analyst Ratings, Price Targets, Predictions
Olema Pharmaceuticals inc has a consensus price target of $20.43, established from looking at the 19 latest analyst ratings. The last 3 analyst ratings were released from Goldman Sachs, Oppenheimer, and HC Wainwright & Co. on April 2, 2024, March 12, 2024, and March 12, 2024. With an average price target of $23.33 between Goldman Sachs, Oppenheimer, and HC Wainwright & Co., there's an implied 129.89% upside for Olema Pharmaceuticals inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Oppenheimer
HC Wainwright & Co.
Citigroup
JP Morgan
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Olema Pharmaceuticals
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/02/2024 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 136.45% | Goldman Sachs | Richard Law | → $24 | Initiates | → Buy | Get Alert |
| 03/12/2024 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 106.9% | Oppenheimer | Matthew Biegler | $21 → $21 | Reiterates | Outperform → Outperform | Get Alert |
| 03/12/2024 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 146.31% | HC Wainwright & Co. | Emily Bodnar | $28 → $25 | Maintains | Buy | Get Alert |
| 01/30/2024 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 97.04% | Citigroup | Yigal Nochomovitz | → $20 | Initiates | → Buy | Get Alert |
| 10/11/2023 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 175.86% | HC Wainwright & Co. | Emily Bodnar | → $28 | Reiterates | Buy → Buy | Get Alert |
| 09/15/2023 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 87.19% | JP Morgan | Anupam Rama | $16 → $19 | Maintains | Overweight | Get Alert |
| 09/06/2023 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 106.9% | Oppenheimer | Matthew Biegler | → $21 | Reiterates | Outperform → Outperform | Get Alert |
| 09/05/2023 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 175.86% | HC Wainwright & Co. | Emily Bodnar | $22 → $28 | Maintains | Buy | Get Alert |
| 08/10/2023 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 57.64% | JP Morgan | Anupam Rama | $14 → $16 | Maintains | Overweight | Get Alert |
| 08/09/2023 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 77.34% | Credit Suisse | Richard Law | $16 → $18 | Maintains | Outperform | Get Alert |
| 08/09/2023 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 116.75% | HC Wainwright & Co. | Emily Bodnar | $17 → $22 | Maintains | Buy | Get Alert |
| 07/21/2023 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 106.9% | Oppenheimer | Matthew Biegler | → $21 | Initiates | → Outperform | Get Alert |
| 05/11/2023 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 67.49% | HC Wainwright & Co. | Emily Bodnar | $14 → $17 | Maintains | Buy | Get Alert |
| 03/10/2023 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 8.37% | Credit Suisse | Richard Law | $12 → $11 | Maintains | Outperform | Get Alert |
| 03/10/2023 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 47.78% | HC Wainwright & Co. | Emily Bodnar | $12 → $15 | Maintains | Buy | Get Alert |
| 02/22/2023 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 18.23% | Credit Suisse | Richard Law | → $12 | Initiates | → Outperform | Get Alert |
| 07/06/2022 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | 57.64% | Canaccord Genuity | William Maughan | → $16 | Assumes | → Buy | Get Alert |
| 06/10/2022 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | — | HC Wainwright & Co. | Emily Bodnar | — | Upgrade | Neutral → Buy | Get Alert |
| 02/28/2022 | OLMA | Buy Now | Olema Pharmaceuticals | $10.15 | — | HC Wainwright & Co. | Emily Bodnar | — | Initiates | → Neutral | Get Alert |
FAQ
What is the target price for Olema Pharmaceuticals (OLMA)?
The latest price target for Olema Pharmaceuticals (NASDAQ: OLMA) was reported by Goldman Sachs on April 2, 2024. The analyst firm set a price target for $24.00 expecting OLMA to rise to within 12 months (a possible 136.45% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Olema Pharmaceuticals (OLMA)?
The latest analyst rating for Olema Pharmaceuticals (NASDAQ: OLMA) was provided by Goldman Sachs, and Olema Pharmaceuticals initiated their buy rating.
When was the last upgrade for Olema Pharmaceuticals (OLMA)?
The last upgrade for Olema Pharmaceuticals inc happened on June 10, 2022 when HC Wainwright & Co. raised their price target to N/A. HC Wainwright & Co. previously had a neutral for Olema Pharmaceuticals inc.
When was the last downgrade for Olema Pharmaceuticals (OLMA)?
There is no last downgrade for Olema Pharmaceuticals.
When is the next analyst rating going to be posted or updated for Olema Pharmaceuticals (OLMA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Olema Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Olema Pharmaceuticals was filed on April 2, 2024 so you should expect the next rating to be made available sometime around April 2, 2025.
Is the Analyst Rating Olema Pharmaceuticals (OLMA) correct?
While ratings are subjective and will change, the latest Olema Pharmaceuticals (OLMA) rating was a initiated with a price target of $0.00 to $24.00. The current price Olema Pharmaceuticals (OLMA) is trading at is $10.15, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.